Eli Lilly's experimental drug orforglipron showed positive results in clinical trials, potentially revolutionizing the treatment of obesity and diabetes with an easy-to-take daily pill. Unlike existing GLP-1 drugs like Wegovy, which require weekly injections, orforglipron aims to provide similar weight loss effects in pill form. The company plans to seek FDA approval for weight loss later this year, followed by diabetes approval early next year. If approved, analysts predict orforglipron could be on the market by late next year, significantly impacting patient access.
The experimental drug, developed by Eli Lilly and known as orforglipron, is a type of medication known as a GLP-1.
If orforglipron can deliver similar results in an easy-to-take pill form, it has the potential to reach many more patients and become a major blockbuster.
Wall Street analysts said that if all went smoothly, orforglipron could become available in the United States sometime in the second half of next year.
Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes.
Collection
[
|
...
]